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Abstract
Purpose To investigate whether the
observed international differences in
retinopathy of prematurity (ROP) treatment
rates within the Beneﬁts of Oxygen
Saturation Targeting (BOOST) II trials might
have been caused by international variation
in ROP disease grading.
Methods Groups of BOOST II trial
ophthalmologists in UK, Australia, and New
Zealand (ANZ), and an international
reference group (INT) used a web based
system to grade a selection of RetCam images
of ROP acquired during the BOOST II UK
trial. Rates of decisions to treat, plus disease
grading, ROP stage grading, ROP zone
grading, inter-observer variation within
groups and intra-observer variation within
groups were measured.
Results Forty-two eye examinations were
graded. UK ophthalmologists diagnosed treat-
requiring ROP more frequently than ANZ
ophthalmologists, 13.9 (3.49) compared to 9.4
(4.46) eye examinations, P= 0.038. UK
ophthalmologists diagnosed plus disease
more frequently than ANZ ophthalmologists,
14.1 (6.23) compared to 8.5 (3.24) eye
examinations, P= 0.021. ANZ ophthalmologists
diagnosed stage 2 ROP more frequently than
UK ophthalmologists, 20.2 (5.8) compared to
12.7 (7.1) eye examinations, P=0.026. There
were no other signiﬁcant differences in the
grading of ROP stage or zone. Inter-observer
variation was higher within the UK group than
within the ANZ group. Intra-observer variation
was low in both groups.
Conclusions We have found evidence of
international variation in the diagnosis of
treatment-requiring ROP. Improved
standardisation of the diagnosis of treatment-
requiring ROP is required. Measures might
include improved training in the grading of
ROP, using an international approach, and
further development of ROP image analysis
software.
Eye advance online publication, 28 July 2017;
doi:10.1038/eye.2017.150
Introduction
Retinopathy of prematurity (ROP) is graded
using the International Classiﬁcation of
Retinopathy of Prematurity (ICROP).1 While
standard images are provided in ICROP,
examiners must use subjective judgement when
describing ROP in an infant. Variation in the
rates of severe ROP between clinical centres
have been attributed in part to observer bias.2 A
number of studies have demonstrated inter-
observer variation when grading ROP using
retinal images.3–10
Five international, multicentre randomised
controlled trials of oxygen saturation targeting in
very premature infants have recently been
reported. The trial protocols were prospectively
aligned to facilitate meta-analysis, the NeOProM
collaboration.11 The trials were performed in
UK,12,13 Australia,12,13 New Zealand,12,14
Canada,15 and USA.16,17
The Beneﬁts of Oxygen Saturation Targeting
(BOOST) II trials performed in UK, Australia,
and New Zealand reported outcomes at the time
of hospital discharge in 2013.12 While the
participants (premature infants) were broadly
similar across countries, a large difference in
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ROP treatment rates was noted.12 153/798 (19.2%) of
enroled infants were treated in the UK, compared to
75/975 (7.7%) in Australia and 23/306 (7.5%) in New
Zealand.12 All ophthalmologists in the BOOST II trials
were instructed to base their decision to treat on the
ETROP18 deﬁnition of Type 1 ROP, however subjective
interpretation of ROP disease signs may have varied
between countries.
Within the BOOST II UK trial, ophthalmologists in 12 of
the 34 trial centres used RetCam imaging (Natus Medical,
Pleasanton, CA, USA) for ROP screening.19 Imaging was
not performed in the other UK centres. These images gave
us the opportunity to compare ROP grading decisions
made by ophthalmologists in the UK, Australia, and New
Zealand who participated in the BOOST II trials. An
international reference group was used as the gold
standard. We aimed to determine whether international
variation in the interpretation of images and subsequent
treatment decisions was present, evidenced in our
opportunistic cohort.
Materials and methods
Ophthalmologists participating in the BOOST II trials
Within the BOOST II trials, local ophthalmology services
for routine ROP screening and treatment were used. In
the UK, BOOST II UK trial ophthalmologists were asked
to attend a training session on ROP classiﬁcation, and
were provided with printed training materials. In
Australia and New Zealand, all BOOST II trial
ophthalmologists were asked to self-certify prior to the
trials, using a training and assessment website http://
www.boostnz.info/ROP/.
Readers
Nine readers from Australia, two from New Zealand, and
seven from UK who participated in the BOOST II trials
were used (Supplementary Information). The groups
from Australia and New Zealand were combined (ANZ)
because the number of readers from New Zealand was
low, and because ophthalmologists in Australia and New
Zealand have a close working relationship for training
and clinical practice. An international reference group of
six experienced ophthalmologists with an interest in ROP
who had not participated in the trials was used as the
‘gold standard’ (INT) (Supplementary Information). The
international reference readers were from UK (2), USA (2),
Canada (1), and Australia (1). The median (range) number
of year’s experience of the readers in performing clinical
ROP screening examinations was 25 (14–26) for the UK
group, 15 (3.5–40) for ANZ, and 21 (10–38) for the
international reference group.
Reading experiments
Each reader logged on to the study website and was given
detailed instructions on how to classify the study images.
Readers were referred to ICROP,1 but standard
comparison images were not given. To protect patient
anonymity, no clinical data were provided. For each eye
examination, drop down menus were used to grade ROP,
and a decision to ‘treat’ or ‘not treat’. The order of eye
examinations was randomised each time a reader logged
on. On completion of grading, data were downloaded to
an Excel spreadsheet for analysis.
Eye examination images
Images were selected by the lead study ophthalmologist
(BWF) for high image quality and readability. An eye
‘examination’ was a set of one to ﬁve images obtained
when examining one eye of one infant on one occasion.
All selected eye examinations were performed prior to
treatment. Forty-two eye examinations obtained from six
centres were used (Supplementary Information). In some
infants more than one eye examination was used, to
ensure a range of ROP disease severity was available for
review. When more than one examination was used from
the same infant, each examination was performed on a
different date. In 31 infants one eye examination was
used, in 3 infants two examinations were used, and in one
infant ﬁve examinations were used. Six of the 42 eye
examinations, illustrating a range of ROP severity, were
duplicated to allow measurement of intra-observer
variation. Each reader assessed 48 eye examinations.
Seventeen of the 42 (40.5%) image sets were obtained at
the time when a decision to treat was made, or
immediately prior to treatment. Thirteen of the 42 (31.0%)
image sets were from infants who did not require
treatment at the time of imaging, but who were
subsequently treated. Twelve of the 42 (28.6%) image sets
were from infants who were not treated for ROP at
any time.
Infants
RetCam images from 35 infants were used, linked to
clinical data from the BOOST II UK trial. Thirty-four
infants were white, one was British Pakistani. Seventeen
(48.6%) infants were female and 18 were male. The mean
gestational age was 25+2 weeks, range 22+6–27+6 weeks.
The mean (SD) birth weight was 785 (170) g, range
366–1115 g. Twenty-three of the 35 (65.7%) infants were
treated for ROP at some time in their clinical course.
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Statistical analysis
Descriptive statistics were used to summarise data
according to type and distribution using counts/
percentages for categorical data, means (standard
deviations [SD]) for normally distributed continuous
variables, and medians (ranges) for other continuous
variables. Data obtained from duplicate eye examinations
were only used for the calculation of intra-observer
variation and were excluded from all other analyses.
Inter-observer variation (Fleiss kappa) and intra-observer
(Cohen kappa) values were calculated using the online
tool www.statstodo.com. Conventionally, a kappa of 0.2
or less is considered poor agreement, 0.21–0.4 fair,
0.41–0.6 moderate, 0.61–0.8 strong and more than 0.8 near
complete agreement.20 These terms were used when
reporting our results.
Results
Treatment decisions
Of the 42 eye examinations reviewed the mean (SD)
number of examinations per reader judged to require
treatment was 13.9 (3.49) for UK readers, 9.4 (4.46) for
ANZ readers, and 12.8 (5.49) for the international readers.
The difference between UK and ANZ readers was
signiﬁcant (t-test P= 0.038, mean difference= 4.49, 95%
CI= 0.27–8.72).
Plus disease
Of the 42 eye examinations reviewed the mean (SD)
number of examinations per reader judged as ‘plus’
disease was 14.1 (6.23) for UK readers, 8.5 (3.24) for ANZ
readers, and 13.2 (6.31) for the international readers
(Table 1). The difference between UK and ANZ readers
was signiﬁcant (t-test P= 0.021, mean difference= 5.69,
95% CI= 0.98–10.40).
Stage of retinopathy of prematurity
For each reader, the number of examinations read for each
ROP stage was calculated. The mean (SD) for each reader
group is given in Table 2. The mean number of eye
examinations per reader classiﬁed as stage 2 was higher in
the ANZ group than in the UK group (t-test, P= 0.026,
mean difference= 7.47, 95% CI= 1.00–13.94). For stage 3
there were no signiﬁcant differences between the groups.
Zone
For each reader, the number of examinations read for each
ROP zone was calculated. The mean (SD) for each reader
group is given in Table 3. The proportion of eye
examinations read as each zone was not signiﬁcantly
different between any pair of groups.
Inter-observer variation
Inter-observer variation Fleiss kappa measures for each
classiﬁcation variable are given in Table 4. Inter-observer
agreement for the whole group of readers was ‘fair’ or
‘moderate’ for all measures. Agreement was highest
within the ANZ group for all measures, with ‘moderate’
agreement for treatment decisions and for plus disease
categories. Agreement was ‘fair’ for treatment decisions
within the UK group. Agreement was poor for most
measures within the INT group.
Intra-observer variation
We measured intra-observer variation by including six
duplicate examinations within the 48 eye examinations
shown to each reader. The results are shown in Table 5.
All kappa values were within the ‘strong’ or ‘near perfect’
agreement categories.
Discussion
We have compared the ROP grading decisions of BOOST
II trial ophthalmologists in UK with those in Australia
and New Zealand. UK ophthalmologists demonstrated a
lower threshold to treat than Australian and New
Zealand ophthalmologists. UK ophthalmologists graded
more images as plus disease, and more images as
treatment-requiring. There were no signiﬁcant differences
in grading stage 3 disease or ROP zone. The UK
ophthalmologists had more inter-observer variation than
the Australian and New Zealand ophthalmologists. Intra-
observer consistency appeared to be good among all
ophthalmologists. The international reference
ophthalmologists graded in a similar way to the UK
ophthalmologists.
There were a number of limitations in our study. While
the data were obtained within the context of a clinical
trial, RetCam images and ROP clinical data were obtained
from routine clinical screening examinations. RetCam
imaging was used in a limited number of centres during
Table 1 The mean (SD) number of eye examinations per reader
classiﬁed as plus disease by reader group (N= 42)
Reader
group
Plus
disease
Pre-Plus
disease
No Plus
disease
Unable to
assess
UK 14.1 (6.2) 15.3 (5.8) 12.1 (7.6) 0.4 (0.5)
ANZ 8.5 (3.2) 13.6 (5.6) 19.6 (6.2) 0.3 (0.7)
INT 13.2 (6.3) 13.5 (1.8) 15.2 (6.2) 0.00
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the BOOST II UK trial, and in some centres was only used
immediately prior to treatment. The quality of images
obtained was variable. The completeness of
accompanying clinical data from the treating
ophthalmologists was variable. The set of RetCam images
used for the study was selected, not random. The groups
of readers from each country were biased towards
experienced, research-active ophthalmologists. The
international reference group was limited in number, and
may not have been truly representative of broad-based
international expertise. The sample size of both RetCam
images and of readers was small and therefore of
insufﬁcient power to detect all but the largest differences.
The context of this study was a group of ﬁve oxygen
trials in premature infants—the NeOProM
collaboration.11 Signiﬁcant differences in ROP treatment
rates between countries were evident. Within the BOOST
II trials performed in UK, Australia, and New Zealand,
153/798 (19.2%) of enroled infants were treated in the UK,
compared to 75/975 (7.7%) in Australia and 23/306
(7.5%) in New Zealand.12 Thus, in the UK 153 infants
were treated, and 645 were not treated. In Australia and
New Zealand combined (ANZ), 98 were treated and 1183
were not treated. The difference in treatment rates was
signiﬁcant (Chi squared test Po0.0001, odds ratio= 2.51,
95% CI= 1.98–3.18). In the Canadian COT trial, 130/1003
(13%) of trial survivors at 36 weeks postmenstrual age
had undergone ROP treatment or had Stage 4 or 5 ROP.15
In the American SUPPORT trial, 120/913 (13.1%) of trial
survivors at 36 weeks postmenstrual age had undergone
ROP treatment or had been diagnosed as having Type 1
ETROP.18 If the Canadian and USA trials are
combined,15,16 250 of 1916 (13.0%) were treated. The
difference in treatment rates between the North American
trials and the ANZ trial was signiﬁcant (Chi squared test
Po0.0001, odds ratio= 1.71, 95% CI= 1.37–2.13), and the
difference in treatment rates between the UK trial and the
North American trials was also signiﬁcant (Chi squared
test Po0.0001, odds ratio= 1.47, 95% CI= 1.22–1.77).
These differences are unlikely to be due to chance.
The baseline clinical characteristics of infants enroled in
the BOOST II UK, BOOST II Australia and the BOOST
New Zealand trials were very similar.12 In addition, the
measured oxygen treatments given to the infants in the
trials were very similar, as were morbidity measures
(other than treatment for ROP), and mortality.12 The
cohorts enroled in the Canadian and USA trials15,16 were
also similar to those in the BOOST II trials. It is therefore
unlikely that the difference in treatment rates between the
individual studies was due to differences in the patient
populations.
Different treatment rates could potentially result in
different visual outcomes. The 2 year outcome data from
the UK and Australian trials13 and from the New Zealand
trial14 gave visual outcome data. In the UK 23 of 718
infants (3.2%), in Australia 5 of 911 infants (0.55%), and in
New Zealand 1 of 340 infants (0.29%) had severe visual
impairment. Additional information was available for the
subgroup of UK infants treated with the revised oxygen
algorithm.13 Eighteen of 551 (3.3%) had severe visual
impairment. Four of these had retinal detachment, 12 had
cerebral visual impairment and in two the cause was not
recorded. Thus 4 of 551 (0.73%) had severe visual
Table 2 The mean (SD) number of eye examinations per reader classiﬁed as each stage of ROP by reader group (N= 42)
Group No ROP Stage 1 Stage 2 Stage 3 AP-ROP Unclassiﬁed
UK 2.6 (1.1) 5.7 (2.9) 12.7 (7.1) 13.9 (4.0) 3.0 (1.6) 4.0 (3.1)
ANZ 2.6 (0.7) 3.8 (3.0) 20.2 (5.8) 11.0 (3.9) 2.0 (1.1) 2.3 (3.1)
INT 3.0 (0.6) 1.7 (2.4) 16.8 (2.5) 15.0 (4.3) 2.2 (1.6) 3.3 (4.8)
Table 3 The mean (SD) number of eye examinations per reader
assessed for each ROP zone by reader group (N= 42)
Reader group Zone I Zone II Zone III Unclassiﬁed
UK 5.9 (3.8) 28.7 (4.7) 7.0 (4.4) 1.3 (1.7)
ANZ 4.0 (3.5) 31.0 (4.5) 4.7 (3.7) 1.7 (1.7)
INT 6.0 (4.7) 26.0 (7.9) 6.4 (5.2) 2.5 (1.9)
Table 4 Inter-observer variation kappa statistics
Group Treatment decisions Plus disease ROP stage ROP zone
UK 0.33 0.2 0.25 0.12
ANZ 0.45 0.45 0.35 0.27
INT 0.19 0.18 0.27 0.13
All 0.35 0.3 0.31 0.22
Table 5 Intra-observer variation weighted Cohen kappa
statistics
Measure Treatment decisions Plus disease ROP stage ROP zone
UK 0.95 0.84 0.92 0.74
ANZ 0.91 0.81 0.84 0.63
INT 0.72 0.91 0.9 0.88
All 0.88 0.85 0.88 0.83
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impairment due to retinal detachment. The lower
treatment rate in ANZ did not result in a higher rate of
severe visual impairment.
Differences in ROP treatment rates have been
documented between centres,2,21 between countries,22,23
and over time.9,24–26 Some variation may be due to
differences in the clinical characteristics of the populations
under study, and to neonatal care practices. This is likely
to be the case when comparing countries with differing
health service characteristics and over periods of
time.9,22,24,25 The clinical characteristics of the infants in
the BOOST II trials were very similar.12,13 In this study,
we have explored the possible contribution to the
observed different rates of ROP treatment of international
variation in disease grading.2,9 Our results suggest such
variation was present.
While inter-observer agreement for plus disease
grading was ‘moderate’ within the ANZ group, it was
‘poor’ for the UK group. Previous studies have also found
limited agreement between experts in the diagnosis of
treatment-requiring ROP,10,27 and of plus disease.10
Gschliesser found moderate inter-observer agreement
(kappa 0.41) for the necessity for treatment, and ‘fair’
agreement (kappa 0.32) for plus disease.10 Chiang found
‘fair’ and ‘moderate’ weighted kappa agreement for the
diagnosis of plus disease when each of a group of experts
was compared to all the other experts in the group.5
While standardisation of ROP diagnostic grading may
be approached by improved training of screening
ophthalmologists,28,29 an international approach is
needed. Tools such as online training and assessment
websites may be used. In Australia and New Zealand all
BOOST II study ophthalmologists were asked to self-
certify prior to the trials, using http://www.boostnz.
info/ROP/.
The key component in ROP treatment decisions is the
detection of plus disease, as deﬁned by ICROP.1 Our
study, and a number of other studies,5 show the
limitations of clinical judgement based on reference
photographs. As has occurred in diabetic retinopathy
screening, a move towards the use of retinal images rather
than clinical examinations is a prerequisite for the
standardisation of diagnostic decisions.30,31
Computerised image analysis techniques, trained by
clinical experts, are needed to improve the objectivity of
treatment decisions.30–39
The planning of international ROP treatment trials
requires improved training and standardisation of
observers. In the Cryotherapy for ROP study, a second
examiner was required to examine each infant within
3 days of the primary examiner, to conﬁrm the presence
of treatment-requiring ‘threshold’ disease.40 In 12% of
cases, the two examiners disagreed on the presence of
plus disease.27,40 Ideally, retinal images should be used in
trials, with central reading centres.41 Both clinical trials
and clinical practice will beneﬁt from the use of image
analysis software that quantiﬁes plus disease.
We found international variation in the diagnosis of
treatment-requiring ROP. While excessively low rates of
ROP treatments risk blindness, excessively high rates of
ROP treatments should also be avoided. Treatment is
invasive, and carries risks of ocular and systemic
morbidity. Improved standardisation of treatment
decisions is an important goal. Approaches might include
the use of internationally standardised online training
tools, and the development of image analysis software to
quantify ROP plus disease.
Summary
What was known before
K Differences in ROP treatment rates have been documented
between centres, between countries, and over time. These
may have occurred for a number of reasons. ROP
treatment rates varied between countries in the BOOST II
trials. A number of studies have found variability between
experts in the diagnosis of treatment-requiring ROP, and
of plus disease.
What this study adds
K In retinal image ROP grading experiments, BOOST II UK
trial ophthalmologists were more likely to diagnose plus
disease, and treatment-requiring ROP than BOOST II trial
ophthalmologists in Australia and New Zealand. As the
patient populations were very similar in the BOOST II
trials, it is likely that variation in treatment rates between
countries was due to international variation in ROP
grading and treatment decisions.
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